U.S., April 12 -- ClinicalTrials.gov registry received information related to the study (NCT06924749) titled 'Study of of Oxygen Nebulized Inhalation EGCG in Cancer Patients With New Coronary Pneumonia' on Aug. 22, 2023.
Brief Summary: Epigallocatechin-3-gallate (EGCG) is a major polyphenol of green tea that possesses a wide variety of actions, such as anti-inflammatory, anti-fibrotic, pro-apoptotic, anti-tumorous, and metabolic effects via modulation of a variety of intracellular signaling cascades. In addition, preclinical studies have also emphasized the antiviral activity of epigallocatechin-3-gallate (EGCG), including SARS-CoV-2. In previous studies, we found that EGCG can prevent and cure radiation- induced normal tissue damage in tu...